Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2004 Mar 29;18(2):139–147. doi: 10.1002/jcla.20012

Reference distributions for alpha2‐macroglobulin: A practical, simple and clinically relevant approach in a large cohort

Robert F Ritchie 1,✉, Glenn E Palomaki 1, Louis M Neveux 1, Olga Navolotskaia 1, Thomas B Ledue 1, Wendy Y Craig 1
PMCID: PMC6807892  PMID: 15065215

Abstract

In this 11th article in a series, reference values of serum levels alpha2‐macroglobulin α2M) are examined. The study is based on a cohort of 40,420 Caucasian individuals from northern New England that were tested in our laboratory between 1994 and 2000. Measurements were standardized against Certified Reference Material (CRM 470)/Reference Preparation for Proteins in Human Serum (RPPHS) and the results analyzed using a previously described statistical approach. Individuals with unequivocal laboratory evidence of inflammation (C‐reactive protein >10 mg/L) were excluded in one leg of the study and included in the other, confirming that α2M does not respond to acute phase drive in man. Nephrotic syndrome, diabetes mellitus, and chronic liver disease have significant effect on levels of α2M. Dramatic changes occur during life with males higher from birth to age 12, females thereafter have higher values until the ninth decade. When values were expressed as multiples of the age‐ and gender‐specific median levels, the resulting distributions fitted a log‐Gaussian distribution well over a broad range. When patient data are normalized in this manner, the distribution parameters can be used to assign a centile corresponding to an individual's measurement thus simplifying interpretation. J. Clin. Lab. Anal. 18:139–147, 2004. © 2004 Wiley‐Liss, Inc.

Keywords: reference range, Caucasian, Alpha2‐macroglobulin, CRM 470/RPPHS, acute phase response

Contributor Information

Robert F. Ritchie, Email: ritchie@fbr.org.

Glenn E. Palomaki, Email: palomaki@fbr.org

REFERENCES

  • 1. Jinbo T, Sakamoto T, Yamamoto S. Serum alpha2‐macroglobulin and cytokine measurements in and acute inflammatory model in rats. Lab Anim 2002;36:153–157. [DOI] [PubMed] [Google Scholar]
  • 2. Souza CT, Moura MB, Magalhaes A, et al. Inhibition of mutalysin II, a metaloproteinase from bushmaster snake venom by human alpha2‐macroglobulin and rabbit immunoglobulin. Comp Biochem Physiol B Biochem Mol Biol 2001;130:155–168. [DOI] [PubMed] [Google Scholar]
  • 3. Wallmo L, Gyzander E, Karlsson K, Lindstedt G, Radberg T, Teger‐Nilsson AC. Alpha 2‐antiplasmin and alpha 2‐macroglobulin—the main inhibitors of fibrinolysis—during the menstrual cycle, pregnancy, delivery and treatment with oral contraceptives. Acta Obstet Gynecol Scand 1982;61:415–422. [DOI] [PubMed] [Google Scholar]
  • 4. Ramcharan S, Sponzilli EE, Wingerd JC. Serum protein fractions. Effects of oral contraceptives and pregnancy. Obstet Gynecol 1976;48:211–215. [PubMed] [Google Scholar]
  • 5. de Sain‐van der Velden MG, Rabelink TJ, Reijngoud DJ, et al. Plasma alpha 2 macroglobulin is increased in nephrotic patients as a result of increased synthesis alone. Kidney Int 1998;54:530–535. [DOI] [PubMed] [Google Scholar]
  • 6. Aviles‐Santa L, Alpern R, Raskin P. Reversible renal failure and nephrotic syndrome in a type 1 diabetic patient. J Diabetes Complications 2002;16:249–254. [DOI] [PubMed] [Google Scholar]
  • 7. McMillan DE. Alpha2‐macroglobulin in diabetes. Lancet 1976;2:1020–1021. [DOI] [PubMed] [Google Scholar]
  • 8. Lynn KL, Frendin TJ, Walker RJ, Bailey RR, Swainson CP. Renal disease in diabetics–which patients have diabetic nephropathy and what is their outcome? Aust N Z J Med 1988;18:764–767. [DOI] [PubMed] [Google Scholar]
  • 9. James K, Merriman J, Gray RS, Duncan LJ, Herd R. Serum alpha 2‐macroglobulin in diabetes. J Clin Pathol 1980;33:163–166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Wilmer WA, Hebert LA, Lewis EJ, et al. Remission of nephrotic syndrome in type 1 diabetes: long‐term follow‐up of patients in the Captopril Study. Am J Kidney Dis 1999;34:308–314. [DOI] [PubMed] [Google Scholar]
  • 11. Davis A. Renal disease, overview In: Ritchie RF, Navolotskaia O, editors. Serum proteins in clinical medicine, volume II, clinical section. Scarborough, Maine: Foundation for Blood Research; 1999. p 116.00.1–4. [Google Scholar]
  • 12. Goldman M, Herbert D, Geary DF. Management of steroid‐sensitive nephrotic syndrome in children with type 1 diabetes. Pediatr Nephrol 2002;17:351–354. [DOI] [PubMed] [Google Scholar]
  • 13. Dornan TL, Jenkins S, Cotton RE, Tattersall RB, Burden RP. The nephrotic syndrome at presentation of insulin‐dependent diabetes mellitus; cause or coincidence. Diabet Med 1988;5:387–390. [DOI] [PubMed] [Google Scholar]
  • 14. Ceriello A, Quatraro A, Dello Russo P, Marchi E, Barbanti M, Giugliano D. Hyperglycemia‐conditioned increase in alpha‐2‐macroglobulin in healthy normal subjects: a phenomenon correlated with deficient antithrombin III activity. Acta Haematol 1989;82:61–63. [DOI] [PubMed] [Google Scholar]
  • 15. Kramer L, Horl WH. Hepatorenal syndrome. Semin Nephrol 2002;22:290–301. [PubMed] [Google Scholar]
  • 16. Briglia AE, Anania FA. Hepatorenal syndrome. Definition, pathophysiology, and intervention. Crit Care Clin 2002;18:345–373. [DOI] [PubMed] [Google Scholar]
  • 17. Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC. Alpha‐2‐macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci 1994;39:2426–2432. [DOI] [PubMed] [Google Scholar]
  • 18. Laurell C‐B, Jeppsson J‐O. Protease inhibitors in plasma In: Putnam F, editor. The plasma proteins. structure, function and genetic control. Volume 1 New York: Academic Press; 1975. p 229–264. [Google Scholar]
  • 19. Mahour GH, Song MK, Adham NF, Rinderknecht H. Alpha2‐macroglobulin deficiency in a patient with Ehlers‐Danlos syndrome. Pediatrics 1978;61:894–897. [PubMed] [Google Scholar]
  • 20. Bergqvist D, Nilsson IM. Hereditary alpha 2‐macroglobulin deficiency. Scand J Haematol 1979;23:433–436. [PubMed] [Google Scholar]
  • 21. Raubenstine DA, Ballantine TVN, Greecher CP, Webb SL. Neonatal serum protein levels as indicators of nutritional status: normal values and correlation with anthropometric data. J Pediatr Gastroenterol Nutr 1990;10:53–61. [DOI] [PubMed] [Google Scholar]
  • 22. Matthijs G, Devriendt K, Cassiman JJ, Van den Berghe H, Marynen P. Structure of the human alpha‐2 macroglobulin gene and its promotor. Biochem Biophys Res Commun 1992;284:596–603. [DOI] [PubMed] [Google Scholar]
  • 23. Poller W, Barth J, Voss B. Detection of an alteration of the alpha 2‐macroglobulin gene in a patient with chronic lung disease and alpha 2‐macroglobulin deficiency. Hum Genet 1989;183:93–96. [DOI] [PubMed] [Google Scholar]
  • 24. Poller W, Faber JP, Klobeck G, Olek K. Cloning of the human alpha 2‐macroglobulin gene and detection of mutations in two functional domains: the bait region and the thiolester site. Hum Genet 1992;88:313–319. [DOI] [PubMed] [Google Scholar]
  • 25. Du Y, Ni B, Glinn M, et al. Alpha2‐macroglobulin as a beta‐amyloid peptide‐binding plasma protein. J Neurochem 1997;69:299–305. [PubMed] [Google Scholar]
  • 26. Myllykangas L, Polvikoski T, Sulkava R, et al. Genetic association of a2‐macroglobulin with Alzheimer's disease in a Finnish elderly population. Ann Neurol 1996;46:382–390. [PubMed] [Google Scholar]
  • 27. Wetterling T, Tegtmeyer KF. Serum alpha 1‐antitrypsin and alpha 2‐macroglobulin in Alzheimer's and Binswanger's disease. Clin Invest 1994;72:196–199. [DOI] [PubMed] [Google Scholar]
  • 28. Scacchi R, Ruggeri M, Gambina G, Martini MC, Corbo RM. Alpha2‐macroglobulin deletion polymorphism and plasma levels in late onset Alzheimer's disease. Clin Chem Lab Med 2002;40:333–336. [DOI] [PubMed] [Google Scholar]
  • 29. Borth W. Alpha 2‐macroglobulin, a multifunctional binding protein with targeting characteristics. FASAB J 1992;6:3345–3353. [DOI] [PubMed] [Google Scholar]
  • 30. Gunnarson M, Jensen PE. Binding of soluble myelin basic protein to various conformational forms of alpha2‐macroglobulin. Arch Biochem Biophys 1998;359:192–198. [DOI] [PubMed] [Google Scholar]
  • 31. Whicher JT, Ritchie RF, Johnson AM, et al. New international reference preparation for proteins in human serum (RPPHS). Clin Chem 1994;40:934–938. [PubMed] [Google Scholar]
  • 32. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for immunoglobulins A, G and M: a practical, simple and clinically relevant approach in a large cohort. J Clin Lab Anal 1998;12: [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB, Craig WY. Reference distributions for the negative acute phase proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. J Lab Clin Anal 1999;13:273–279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O. Reference distributions for the positive acute phase proteins, α1‐acid glycoprotein (orosomucoid), α1‐antitrypsin, and haptoglobin: a practical, simple, and clinically relevant approach to a large cohort. J Clin Lab Anal 2000;14:284–292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Ritchie RF, Palomaki GE, Navolotskaia O, Neveux LM, Ledue TB, Craig WY. Reference distributions for serum iron and transferrin saturation: a practical, simple, and clinically relevant approach in a large cohort. J Clin Lab Anal 2002;16:237–245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Ritchie RF, Palomaki GE, Navolotskaia O, Neveux LM, Ledue TB, Craig WY. Reference distributions for the complement components C3 and C4: a comparison of a large cohort to the world's literature. J Lab Clin Anal 18:148–152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Ritchie RF, Palomaki GE, Navolotskaia O, Neveux LM, Ledue TB, Craig WY. Reference distributions for alpha2‐macroglobulin: a comparison of a large cohort to the world's literature. J Lab Clin Anal (in press). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Healy MJR. Outliers in clinical chemistry quality‐control schemes. Clin Chem 1979;25:675–677. [PubMed] [Google Scholar]
  • 39. Shiota G, Umeki K, Okano J, Kawasaki H. Hepatocyte growth factor and acute phase proteins with chronic liver diseases. J Med 1995;26:295–304. [PubMed] [Google Scholar]
  • 40. Winslet MC, Sherwell J, Radley S, Keighley MRB. The acute phase protein response in Crohn's colitis. Biochem Soc Trans 1991;19: [DOI] [PubMed] [Google Scholar]
  • 41. Agostoni A, Marasini B, Stabilini R, Del Ninno E, Pontello M. Multivariate analysis of serum protein assays in chronic hepatitis and postnecrotic cirrhosis. Clin Chem 1974;20:428–429. [PubMed] [Google Scholar]
  • 42. Pongpaew P, Schelp FP. Albumin, prealbumin, transferrin and serum proteinase inhibitors in asymptomatic and hospitalized Thai alcohol drinkers. J Stud Alcohol 1983;44:381–383. [DOI] [PubMed] [Google Scholar]
  • 43. Finotti P, Piccoli A, Carraro P. Alteration of plasma proteinase‐antiproteinase system in type 1 diabetic patients. Influence of sex and relationships with metabolic control. Diabetes Res Clin Pract 1992;18:35–42. [DOI] [PubMed] [Google Scholar]
  • 44. Vaziri ND, Gonzales EC, Shayestehfar B, Barton CH. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome. J Lab Clin Med 1994;124:118–124. [PubMed] [Google Scholar]
  • 45. Ledue TB, Johnson MJ, Cohen LA, Ritchie RF. Evaluation of proficiency survey results for serum immunoglobulins following the introduction of a new international reference material for human serum proteins. Clin Chem 1998;44:878–879. [PubMed] [Google Scholar]
  • 46. Banks RE, Evans SW, Alexander D, Van Leuven F, Whicher JT, McMahon MJ. Related articles, alpha 2 macroglobulin state in acute pancreatitis. Raised values of alpha 2 macroglobulin‐protease complexes in severe and mild attacks. Gut 1991;32:430–434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Aasen AO, Erichsen NS, Gallimore MJ, Amundsen E. Studies on components of the plasma kallikrein‐kinin system in plasma samples from normal individuals and patients with septic shock. Adv Shock Res 1980;4:1–10. [PubMed] [Google Scholar]
  • 48. McMahon MJ, Bowen M, Mayer AD, Cooper EH. Relation of alpha 2‐macroglobulin and other antiproteases to the clinical features of acute pancreatitis. Am J Surg 1984;147:164–170. [DOI] [PubMed] [Google Scholar]
  • 49. Doherty NS, Littman BH, Reilly K, Swindell AC, Buss JM, Anderson M. Analysis of changes in acute‐phase plasma proteins in an acute inflammatory response and in rheumatoid arthritis using two‐dimensional gel electrophoresis. Electrophoresis 1998;19:355–363. [DOI] [PubMed] [Google Scholar]
  • 50. Van Gool J, van Vugt H, de Bont E. Alpha 2‐macroglobulin and fibrinogen modulate inflammatory edema in man. Inflammation 1990;14:275–283. [DOI] [PubMed] [Google Scholar]
  • 51. Cannon JG, Angel JB, Ball RW, Abad LW, Fagioli L, Kamaroff AL. Acute phase responses and cytokine secretion in chronic fatigue syndrome. J Clin Immunol 1999;19:414–421. [DOI] [PubMed] [Google Scholar]
  • 52. Burnett D, Stockley RA. Serum and sputum alpha 2 macroglobulin in patients with chronic obstructive airway disease. Thorax 1981;36:512–516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Condacci I, Cimasoni G, Ahmad‐Zadeh C. Alpha 2‐macroglobulin in sulci from healthy and inflamed human gingiva. Infect Immunol 1982;36:66–71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54. Tsouris JA, Mehta PD, Patti PJ, et al. Alpha2 macroglobulin elevation without an acute phase response in depressed adults with down's syndrome: implications. J Intellect Disabil Res 2000;44:644–653. [DOI] [PubMed] [Google Scholar]
  • 55. Anneren G, Gebre‐Medhin M. Trace elements and transport proteins in serum of children with Down syndrome and of healthy siblings living in the same environment. Hum Nutr Clin Nutr 1987;41:291–299. [PubMed] [Google Scholar]
  • 56. Makis AC, Hatzimichael EC, Mavridis A, Bourantas KL. Alpha‐2‐macroglobulin and interleukin‐6 levels in steady‐state sickle cell disease patients. Acta Haematol 2001;104:164–168. [DOI] [PubMed] [Google Scholar]
  • 57. Roberts RC, Hall PK, Nikolai TF, McKenzie AK. Reduced trypsin binding capacity of alpha 2‐macroglobulin in diabetics. Clin Chem Acta 1986;154:85–101. [DOI] [PubMed] [Google Scholar]
  • 58. Gray RS, James K, Merriman J, et al. Alpha 2‐macroglobulin and proliferative retinopathy in type 1 diabetes. Horm Metab Res 1982;4:389–392. [DOI] [PubMed] [Google Scholar]
  • 59. Volpi A, Piaserico PL. Alpha2‐macroglobulin in diabetic disease and in its microangiopathic complications. Minerva Med 1983;74:2287–2289. [PubMed] [Google Scholar]
  • 60. Turecky L, Kupcova V, Szantova M. Alpha 2‐macroglobulin in the blood of patients with diabetes mellitus. Bratisl Lek Listy 1999;100:25–27. [PubMed] [Google Scholar]
  • 61. Ahmad J, Singh M, Saleemuddin M. A study of plasma alpha‐2‐macroglobulin levels in type 2 diabetic subjects with microalbuminuria. J Assoc Physicians India. 2001;49:1062–1065. [PubMed] [Google Scholar]
  • 62. Ohtani H. Immunological background of plasma protein abnormalities—the relation between inflammation and malignant neoplasm. Rincho Byori 1999;47:909–916. [PubMed] [Google Scholar]
  • 63. Kanoh Y, Ohtani N, Mashiko T, et al. Levels of alpha 2 macroglobulin can predict bone metastases in prostate cancer. Anticancer 2001;21:551–556. [PubMed] [Google Scholar]
  • 64. Ohtani H, Saito M, Koshiba K. Alpha‐2‐macroglobulin deficiency in patients with advanced prostate cancer. Oncology 1985;42:341–344. [DOI] [PubMed] [Google Scholar]
  • 65. National Committee for Clinical Laboratory Standards . How to define and determine reference intervals in the clinical laboratory: approved guideline. NCCLS document C28‐A. Villanova, PA: NCCLS; 1995. [Google Scholar]
  • 66. Gräsbeck R, Siest G, Wilding P, Williams GZ, Whitehead TP. Provisional recommendation on the theory of reference values. Part 1. The concept of reference values. Clin Chim Acta 1978;87:461F–465F. [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES